Peter Greenleaf Aurinia Pharmaceuticals Inc. (AUPH) insider trading activity

Peter Greenleaf is Chief Executive Officer of Aurinia Pharmaceuticals Inc.. Currently has a direct ownership of 1.85 Million shares of AUPH, which is worth approximately $28.3 Million. The most recent transaction as insider was on Jan 02, 2026, when has been sold 113,169 shares (Common Stock) at a price of $15.95 per share, resulting in proceeds of $1,805,045. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.85M

3.14% 3M change

21.22% 12M change

Total Value Held $28.3 Million

Peter Greenleaf Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2026	SELL Payment of exercise price or tax liability	$1,805,045 $15.95 p/Share	113,169 Reduced 5.78%	1,845,037 Common Stock
Jan 02 2026	BUY Grant, award, or other acquisition	-	165,384 Added 7.8%	1,954,329 Common Stock
Mar 04 2025	SELL Open market or private sale	$1,306,380 $7.92 p/Share	164,947 Reduced 8.44%	1,788,945 Common Stock
Mar 03 2025	SELL Open market or private sale	$1,564,744 $8.0 p/Share	195,593 Reduced 9.1%	1,953,892 Common Stock
Mar 03 2025	BUY Grant, award, or other acquisition	-	333,705 Added 13.44%	2,149,485 Common Stock
Feb 28 2025	BUY Grant, award, or other acquisition	-	290,728 Added 13.8%	1,815,780 Common Stock
Mar 06 2024	SELL Open market or private sale	$711,093 $5.6 p/Share	126,981 Reduced 7.7%	1,522,114 Common Stock

Feb 20 2024	BUY Grant, award, or other acquisition	-	661,538 Added 28.63%	1,649,095 Common Stock
Mar 02 2023	SELL Open market or private sale	$292,785 $8.94 p/Share	32,750 Reduced 3.22%	982,968 Common Stock
Mar 02 2023	BUY Grant, award, or other acquisition	-	667,407 Added 39.65%	1,015,718 Common Stock
Mar 02 2022	SELL Open market or private sale	$108,907 $12.01 p/Share	9,068 Reduced 21.57%	32,967 Common Stock
Mar 02 2022	BUY Grant, award, or other acquisition	-	28,300 Added 40.24%	42,035 Common Stock
May 11 2021	BUY Open market or private purchase	$54,479 $10.63 p/Share	5,125 Added 27.59%	13,453 Common Stock

Also insider at

BDSI

BIODELIVERY SCIENCES INTERNATIONAL INC Healthcare

Director

CHRO

Chromocell Therapeutics Corp

Director

Peter Greenleaf

Chief Executive Officer

Victoria, A1

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AUPH shares.

Notify only if

Value

Insider Trading

Get notified when an Aurinia Pharmaceuticals Inc. insider buys or sells AUPH shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aurinia Pharmaceuticals Inc.

Track Activities on AUPH

Account